Clinical Trial Update: Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

This clinical trial update indicates that a Phase 3 study evaluating hetrombopag for pediatric patients with chronic immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Hetrombopag (hetrombopag)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Immune Thrombocytopenia | Phase 3 | Status: COMPLETED